Refractory Hairy Cell Leukemia

Categories: Blood diseases, Cancer diseases, Immune diseases

Aliases & Classifications for Refractory Hairy Cell Leukemia

MalaCards integrated aliases for Refractory Hairy Cell Leukemia:

Name: Refractory Hairy Cell Leukemia 12 15 70


External Ids:

Disease Ontology 12 DOID:711
NCIt 50 C142882
ICD10 32 C91.42
UMLS 70 C0279780

Summaries for Refractory Hairy Cell Leukemia

Disease Ontology : 12 A refractory hematologic cancer that is a mature B cell cancer that does not yield readily to treatment.

MalaCards based summary : Refractory Hairy Cell Leukemia is related to hairy cell leukemia and capillary leak syndrome. An important gene associated with Refractory Hairy Cell Leukemia is BRAF (B-Raf Proto-Oncogene, Serine/Threonine Kinase), and among its related pathways/superpathways are B cell receptor signaling pathway (KEGG) and Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers. The drugs Ofloxacin and Cefepime have been mentioned in the context of this disorder. Affiliated tissues include bone marrow, bone and t cells, and related phenotype is Reduced mammosphere formation.

Related Diseases for Refractory Hairy Cell Leukemia

Diseases related to Refractory Hairy Cell Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 45)
# Related Disease Score Top Affiliating Genes
1 hairy cell leukemia 31.1 IL2RA CD22 BRAF
2 capillary leak syndrome 30.5 CD22 CD19
3 hemolytic-uremic syndrome 10.4
4 splenomegaly 10.3
5 lymphoproliferative syndrome 10.2
6 pancytopenia 10.2
7 thrombocytopenia 10.2
8 anemia, autoimmune hemolytic 10.0
9 aspergillosis 10.0
10 deficiency anemia 10.0
11 exanthem 10.0
12 neutropenia 10.0
13 hemolytic anemia 10.0
14 lymphopenia 10.0
15 b-cell lymphoma 10.0
16 oligoarticular juvenile idiopathic arthritis 10.0 IL2RA HLA-DRB1
17 idiopathic neutropenia 10.0 IL2RA HLA-DRB1
18 eye lymphoma 10.0 CD22 CD19
19 relapsed/refractory diffuse large b-cell lymphoma 10.0 CD22 CD19
20 alpha chain disease 10.0 CD22 CD19
21 adult lymphoma 10.0 CD22 CD19
22 cystic echinococcosis 10.0 IL2RA HLA-DRB1
23 spleen cancer 10.0 CD22 CD19
24 pure red-cell aplasia 10.0 IL2RA HLA-DRB1
25 cll/sll 10.0 CD22 CD19
26 intermediate uveitis 10.0 IL2RA HLA-DRB1
27 epidermolysis bullosa acquisita 10.0 IL2RA HLA-DRB1
28 lymphoplasmacytic lymphoma 10.0 CD22 CD19
29 panniculitis 10.0 IL2RA BRAF
30 splenic disease 10.0 CD22 CD19
31 b cell prolymphocytic leukemia 10.0 IL2RA CD19
32 prolymphocytic leukemia 10.0 IL2RA CD19
33 autoimmune disease of endocrine system 9.9 IL2RA HLA-DRB1
34 adult acute lymphocytic leukemia 9.9 CD22 CD19
35 hypersensitivity reaction type iv disease 9.8 HLA-DRB1 CD19
36 marginal zone b-cell lymphoma 9.8 CD22 CD19
37 visceral leishmaniasis 9.8 IL2RA HLA-DRB1 EEF2
38 vogt-koyanagi-harada disease 9.8 IL2RA HLA-DRB1
39 diphtheria 9.8 IL2RA FURIN EEF2
40 celiac disease 1 9.7 IL2RA HLA-DRB1 CD19
41 limited scleroderma 9.7 IL2RA HLA-DRB1
42 common variable immunodeficiency 9.6 IL2RA HLA-DRB1 CD19
43 lymphoma, non-hodgkin, familial 9.6 IL2RA CD22 CD19 BRAF
44 leukemia, chronic lymphocytic 9.6 IL2RA CD22 CD19 BRAF
45 refractory hematologic cancer 8.5 MSLN HLA-DRB1 FURIN EEF2 DAP CD22

Graphical network of the top 20 diseases related to Refractory Hairy Cell Leukemia:

Diseases related to Refractory Hairy Cell Leukemia

Symptoms & Phenotypes for Refractory Hairy Cell Leukemia

GenomeRNAi Phenotypes related to Refractory Hairy Cell Leukemia according to GeneCards Suite gene sharing:

# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.02 BRAF CD22 DAP EEF2 IL2RA

Drugs & Therapeutics for Refractory Hairy Cell Leukemia

Drugs for Refractory Hairy Cell Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 246)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Ofloxacin Approved Phase 3 82419-36-1 4583
Cefepime Approved, Investigational Phase 3 88040-23-7 5479537
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
Clotrimazole Approved, Vet_approved Phase 3 23593-75-1 2812
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
Itraconazole Approved, Investigational Phase 3 84625-61-6 55283
Palivizumab Approved, Investigational Phase 3 188039-54-5
Ribavirin Approved Phase 3 36791-04-5 37542
Dalteparin Approved Phase 3 9005-49-6
Tinzaparin Approved Phase 3 9041-08-1, 9005-49-6 25244225
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
Caspofungin Approved Phase 3 179463-17-3, 162808-62-0 468682 2826718
Captopril Approved Phase 3 62571-86-2 44093
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
Iron Approved Phase 3 7439-89-6 23925 29936
Darbepoetin alfa Approved, Investigational Phase 3 209810-58-2, 11096-26-7
Acyclovir Approved Phase 3 59277-89-3 2022
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
Ondansetron Approved Phase 3 99614-02-5 4595
Tazobactam Approved Phase 3 89786-04-9 123630
Vancomycin Approved Phase 3 1404-90-6 14969 441141
Piperacillin Approved Phase 3 66258-76-2 43672
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
Ethinyl Estradiol Approved Phase 3 57-63-6 5991
Polyestradiol phosphate Approved Phase 3 28014-46-2
Moxifloxacin Approved, Investigational Phase 3 354812-41-2, 151096-09-2 152946
Estradiol Approved, Investigational, Vet_approved Phase 3 50-28-2 5757
Norgestimate Approved, Investigational Phase 3 35189-28-7 6540478
St. John's Wort Approved, Investigational, Nutraceutical Phase 3 84082-80-4
Ginseng Approved, Investigational, Nutraceutical Phase 3 50647-08-0
32 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
33 Anesthetics, Dissociative Phase 3
34 Protective Agents Phase 3
35 Cytochrome P-450 CYP3A Inhibitors Phase 3
Hydroxyitraconazole Phase 3 108222
37 Antifungal Agents Phase 3
38 Antiviral Agents Phase 3
39 Cola Phase 3
40 Heparin, Low-Molecular-Weight Phase 3
41 Neurotransmitter Agents Phase 3
42 Narcotics Phase 3
43 Excitatory Amino Acid Antagonists Phase 3
44 Analgesics, Opioid Phase 3
45 Analgesics Phase 3
46 Hematinics Phase 3
protease inhibitors Phase 3
48 Angiotensin-Converting Enzyme Inhibitors Phase 3
49 Antihypertensive Agents Phase 3
50 HIV Protease Inhibitors Phase 3

Interventional clinical trials:

(show top 50) (show all 135)
# Name Status NCT ID Phase Drugs
1 Multicenter, Double-Blind, Randomized Study to Compare the Safety and Efficacy of Levofloxacin With That of Cefepime in the Treatment of Fever and Neutropenia - Phase IIIB Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
2 A Randomized Double-Blind Controlled Trial of Ketamine Versus Placebo in Conjunction With Best Pain Management in Neuropathic Pain in Cancer Patients Unknown status NCT01316744 Phase 3 ketamine hydrochloride
3 A Randomized Double-Blind Placebo-Controlled Phase III Study To Evaluate The Safety And Efficacy Of Palivizumab Combined With Aerosolized Ribavirin Compared To Ribavirin Alone To Treat RSV Pneumonia In Patients With Bone Marrow Transplants (BMT) Completed NCT00014391 Phase 3 ribavirin
4 A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Fragmin (5,000 IU Subcutaneously) in Preventing Catheter-Related Complications When Given Daily to Cancer Patients With Central Venous Catheters Completed NCT00006083 Phase 3 Fragmin
5 Does Hypericum Reduce Fatigue in Cancer Patients on Chemotherapy? A Randomized, Double-Blind, Placebo-Controlled Clinical Trial Completed NCT00005805 Phase 3
6 A Phase III Double-Blind Equivalence Study of Two Different Formulations of Slow-Release Morphine Followed by a Randomization Between Dextromethorphan or Placebo Plus Statex SR for Chronic Cancer Pain Relief in Terminally Ill Patients Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
7 Phase III Study of Captopril in Patients Undergoing Autologous Bone Marrow/Stem Cell Transplantation Completed NCT00004230 Phase 3 captopril;cyclophosphamide
8 A Randomized, Comparative Study of Itraconazole Versus Fluconazole for Prevention of Aspergillus Infections in Peripheral Blood Stem Cell and Marrow Transplant Recipients Completed NCT00003883 Phase 3 fluconazole;itraconazole
9 A Phase III Multicenter Study of Cytomegalovirus Prophylaxis With Valacyclovir for the Prevention of Serious Fungal and Bacterial Infections Among Cytomegalovirus Seronegative Recipients of Cytomegalovirus Seropositive Sx Stem Cell Transplants Completed NCT00045292 Phase 3 acyclovir;acyclovir sodium;valacyclovir
10 A Multicenter, Double-Blind, Randomized, Comparative Study To Evaluate The Safety, Tolerability, And Efficacy Of MK-0991 Versus (Amphotericin B) Liposome For Injection As Empirical Therapy In Patients With Persistent Fever And Neutropenia Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
11 Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer Completed NCT00006348 Phase 3 ondansetron
12 Music Video and Adolescent/Young Adult Resilience During Transplant Completed NCT00305851 Phase 3
13 A Strategic Study to Determine the Optimal Moment to Initiate Systemic Antifungal Therapy With Ambisome in Granulocytopenic Cancer Patients With Unexplained Fever Refractory to Empirical Antibacterials Completed NCT00003938 Phase 3 liposomal amphotericin B
14 Vancomycin Versus Placebo in Persistently Febrile Granulocytopenic Patients Given Piperacillin/Tazobactam Completed NCT00003805 Phase 3 piperacillin sodium;piperacillin-tazobactam;tazobactam sodium;vancomycin
15 Preparatory Aid to Improve Decision Making About Cancer Clinical Trials (PRE-ACT) Completed NCT00750009 Phase 3
16 A Phase III, Randomized Study of the Effects of Parenteral Iron, Oral Iron, or No Iron Supplementation on the Erythropoietic Response to Darbepoetin Alfa for Cancer Patients With Chemotherapy-Associated Anemia Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
17 Phase III Randomized Trial of an Opioid Titration Order Sheet Compared to Standard of Care in Patients With Cancer Related Pain. Completed NCT00666211 Phase 3
18 The Use of American Ginseng (Panax Quinquefolius) to Improve Cancer-Related Fatigue: A Randomized, Double-Blind, Placebo-Controlled Phase III Study Completed NCT00719563 Phase 3 American ginseng
19 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
20 A Pivotal Multicenter Trial of Moxetumomab Pasudotox in Relapsed/ Refractory Hairy Cell Leukemia Completed NCT01829711 Phase 3 Moxetumomab pasudotox;IV Bag Protectant for Moxetumomab pasudotox
21 Randomized, Double Blinded, Placebo-Controlled Trial of Antibacterial Prophylaxis for the Prevention of Bacterial Infections in the Post-Engraftment Phase After Allogeneic Hematopoeitic Stem Cell Transplantation Terminated NCT00324324 Phase 3 moxifloxacin hydrochloride;Placebo
22 A Multiinstitutional Trial To Evaluate The Prophylactic Use Of NASA-Developed Light Emitting Diodes For The Prevention Of Oral Mucositis In Bone Marrow Transplant Patients Unknown status NCT00036712 Phase 2
23 A Phase II Study to Evaluate Efficacy and Tolerability of Methotrexate in Combination With Glucocorticoids for the Treatment of Newly Diagnosed Acute Graft-Versus-Host Disease After Nonmyeloablative Hematopoietic Cell Transplantation Completed NCT00357084 Phase 2 methotrexate;methylprednisolone;prednisone
24 A Phase I Evaluation of the Combination of Pegylated Liposomal Doxorubicin (Doxil®) With PS-341 in Patients With Refractory Hematologic and Solid Malignancies Completed NCT00237627 Phase 1, Phase 2 PS-341;Doxil;Velcade
25 Oral Beclomethasone Dipropionate Capsules for Treatment of Intestinal Graft-Versus-Host Disease: Compassionate Use in Patients With Contraindictions to High-Dose Immunosuppressive Therapy Completed NCT00010283 Phase 1, Phase 2 beclomethasone dipropionate
26 Treatment of Patients With Hematological Malignancies Using Marrow Transplantation From Unrelated Donors Incompatible for One HLA Locus Antigen Completed NCT00005804 Phase 2 cyclophosphamide
27 Adoptive Immunotherapy of Epstein Barr Virus Induced Lymhoproliferative Disease. A Comparison of Allogeneic and Autologous Lymphocyte Responses ex Vivo and Use of Highly Selected Reactive Cells as an Alternative to Chemotherapy in Vivo. Completed NCT00005606 Phase 2
28 Cytokine-Based Immunotherapy Following High-Dose Chemotherapy and Autologous Stem Cell Transplantation Completed NCT00003408 Phase 2
29 A Phase I-II Intensive-Dose Ifosfamide, Carboplatin and Taxotere (IC-T) Combination Chemotherapy Followed by Autologous Stem Cell Rescue for Patients With Refractory Malignancies Completed NCT00003406 Phase 1, Phase 2 carboplatin;docetaxel;ifosfamide
30 Assessment of Early and Standard Intervention With Procrit® (Epoetin Alfa) 120,000 Units Once Every Three Weeks (Q3W) in Patients With Cancer Receiving Chemotherapy Completed NCT00255749 Phase 2
31 A Multicenter, Open, Phase II Study to Estimate the Activity and Safety of Caspofungin (CASP) in the First-Line Treatment of Probable and Proven Invasive Aspergillosis (IA) in Patients With Hematological Malignancies (HM) or Recipients of Autologous Haematopoietic Stem Cell Transplantation and Those With Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) Completed NCT00110045 Phase 2 caspofungin acetate
32 Phase II Clinical Trial Incorporating Alemtuzumab (Campath-1H) in Combination With FK506 and Methylprednisolone for Treatment of Severe Acute Graft vs Host Disease Completed NCT00109993 Phase 2 methylprednisolone;tacrolimus
33 The Effect of Cyproheptadine Hydrochloride (Periactin) and Megestrol Acetate (Megace) on Weight in Children With Cancer/Treatment Related Cachexia Completed NCT00066248 Phase 2 cyproheptadine hydrochloride;megestrol acetate
34 Donor Lymphocyte Infusion (DLI) as Adoptive Immunotherapy for Relapse Malignancies After Allogeneic Hematopoietic Transplantation Completed NCT00003887 Phase 2
36 RC05CB A Pilot, Randomized Comparison of Standard Weekly Epoetin Alfa to Every-3-Week-Epoetin Alfa and Every 3-Week Darbepoetin Alfa Completed NCT00416624 Phase 2 darbepoetin alfa;epoetin alfa
37 A Phase I/II Study of Sirolimus in Addition to Tacrolimus and Methotrexate for the Prevention of Acute-Graft-Versus-Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplantation From Unrelated Donors Completed NCT00089037 Phase 1, Phase 2 methotrexate;sirolimus;tacrolimus
38 A Phase II Study of the Combination of Tacrolimus and Mycophenolate Mofetil for the Prevention of Acute Graft-Versus-Host Disease Completed NCT00096096 Phase 2 mycophenolate mofetil;tacrolimus
39 Phase II Trial Of BL22 Immunotoxin In Hairy Cell Leukemia Completed NCT00074048 Phase 2 BL22
40 A Phase I-II Safety, Tolerability And Pharmacokinetic Study Of Ravuconazole For Prophylaxis Of Invasive Fungal Infections In Patients Undergoing Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation Completed NCT00064311 Phase 1, Phase 2 ravuconazole
41 Rituximab (IDEC-C2B8, Mabthera) in Patients With Hairy Cell Leukemia Relapsing After Treatment With 2-Chlorodeoxyadenosine (CDA) Completed NCT00003757 Phase 2
43 Matched Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplantation With a Conditioning Regimen of Targeted Busulfan, Cyclophosphamide, and Thymoglobulin Completed NCT00611351 Phase 2 busulfan;cyclophosphamide;mycophenolate mofetil;tacrolimus
44 Phase II Study of Allogeneic Transplant of Hematopoietic Stem Cells From a Compatible Family Donor in the Treatment of Patients Over 55 Years With Hematological Malignancies Completed NCT00806767 Phase 2 busulfan;fludarabine phosphate
45 Donor NK Cell Infusion for Progression/Recurrence of Underlying Malignant Disorders After HLA-haploidentical HCT - a Phase 1-2 Study Completed NCT00823524 Phase 1, Phase 2
46 Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia Recruiting NCT01059786 Phase 2 Pentostatin;Rituximab;Bendamustine
47 A Phase II Study of the BRAF Inhibitor, Vemurafenib, in Patients With Relapsed or Refractory Hairy Cell Leukemia Active, not recruiting NCT01711632 Phase 2 Vemurafenib
48 Transplantation of Unrelated Donor Hematopoietic Stem Cells for the Treatment of Hematological Malignancies Terminated NCT00281879 Phase 2 busulfan;carmustine;cyclophosphamide;cyclosporine;cytarabine;etoposide;fludarabine phosphate;melphalan;methotrexate;methylprednisolone;mycophenolate mofetil;tacrolimus
49 A Pilot Phase II Study of Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation Terminated NCT01116232 Phase 2 sirolimus;tacrolimus
50 Allogeneic Bone Marrow Transplantation for Marrow Failure States Terminated NCT00005852 Phase 2 cyclophosphamide;cyclosporine;methylprednisolone

Search NIH Clinical Center for Refractory Hairy Cell Leukemia

Genetic Tests for Refractory Hairy Cell Leukemia

Anatomical Context for Refractory Hairy Cell Leukemia

MalaCards organs/tissues related to Refractory Hairy Cell Leukemia:

Bone Marrow, Bone, T Cells, Liver

Publications for Refractory Hairy Cell Leukemia

Articles related to Refractory Hairy Cell Leukemia:

(show all 44)
# Title Authors PMID Year
Safety and efficacy of the BRAF inhibitor dabrafenib in relapsed or refractory hairy cell leukemia: a pilot phase-2 clinical trial. 61
33731847 2021
Long-term follow-up after rituximab plus bendamustine in a patient with relapsed or refractory hairy cell leukemia variant: A case report. 61
33592897 2021
Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial. 61
33627164 2021
Contextualizing the Use of Moxetumomab Pasudotox in the Treatment of Relapsed or Refractory Hairy Cell Leukemia. 61
31628266 2020
Autoimmune hemolytic anemia in refractory hairy cell leukemia on dabrafenib and trametinib. 61
31410508 2019
Moxetumomab pasudotox for the treatment of relapsed and/or refractory hairy cell leukemia. 61
31298972 2019
Moxetumomab pasudotox: A first-in-class treatment for hairy cell leukemia. 61
30917739 2019
Moxetumomab pasudotox-tdfk for relapsed/refractory hairy cell leukemia: a review of clinical considerations. 61
31134324 2019
Moxetumomab Pasudotox: Clinical Experience in Relapsed/Refractory Hairy Cell Leukemia. 61
31099793 2019
Secondary malignancies after treatment with single-agent vemurafenib in two patients with refractory hairy cell leukemia. 61
30322325 2019
Hairy Cell Leukemia Treatment Approved. 61
30262591 2018
Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia. 61
30030507 2018
Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase 1 results and long-term follow-up. 61
29487070 2018
MRD-negative complete remission in relapsed refractory hairy cell leukemia with bendamustine and obinutuzumab. 61
29285581 2018
Refractory hairy cell leukemia-variant. 61
27727469 2017
Ibrutinib for relapsed refractory hairy cell leukemia variant. 61
27733095 2017
Immunogenicity of therapeutic recombinant immunotoxins. 61
26864110 2016
Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia. 61
26352686 2015
[Pulmonary infection in neutropenia]. 61
25774734 2015
Rapid and complete hematological response of refractory hairy cell leukemia to the BRAF inhibitor dabrafenib. 61
24863690 2014
Treatment of refractory hairy cell leukemia with a BRAF-inhibitor: lessons to be learnt. 61
24789721 2014
Successful vemurafenib salvage treatment in a patient with primary refractory hairy cell leukemia and pulmonary aspergillosis. 61
24337488 2014
Bendamustine and rituximab in relapsed and refractory hairy cell leukemia. 61
24097860 2013
Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression. 61
24154601 2013
Continued response off treatment after BRAF inhibition in refractory hairy cell leukemia. 61
23690412 2013
[Successful use of vemurafenib in a patient with resistant hairy cell leukemia]. 61
24137951 2013
BRAF inhibition in refractory hairy-cell leukemia. 61
22621641 2012
Hematologic improvement after flavopiridol treatment of pentostatin and rituximab refractory hairy cell leukemia. 61
22165992 2012
Fludarabine and rituximab for relapsed or refractory hairy cell leukemia. 61
22223825 2012
Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox. 61
22003067 2011
Recombinant immunotoxins and other therapies for relapsed/refractory hairy cell leukemia. 61
21599609 2011
[Successful treatment of refractory hairy cell leukemia with rituximab]. 61
19764485 2009
Achievement of complete remission of refractory hairy cell leukemia by rituximab progressing after allogeneic hematopoietic stem cell transplantation. 61
19330554 2009
[Complete remission after Rituximab treatment in refractory hairy cell leukemia]. 61
18570771 2008
Effective treatment of a refractory hairy cell leukemia variant with splenic pre-irradiation and alemtuzumab. 61
18259114 2008
The role of rituximab in combination with pentostatin or cladribine for the treatment of recurrent/refractory hairy cell leukemia. 61
17886250 2007
Immunotoxins in the treatment of refractory hairy cell leukemia. 61
16990113 2006
[Successful rituximab treatment in a patient with refractory hairy cell leukemia-Japanese variant and suffering from acute respiratory distress]. 61
16440803 2005
Successful induction of long-term remission using rituximab in a patient with refractory hairy cell leukemia-Japanese variant. 61
15646655 2004
Rituximab in relapsed or refractory hairy cell leukemia. 61
12816862 2003
Responses in refractory hairy cell leukemia to a recombinant immunotoxin. 61
10552943 1999
Subchronic toxicity of pentostatin in Wistar rats. 61
7899780 1994
Improved production of pentostatin and identification of fermentation cometabolites. 61
1490883 1992
Fludarabine phosphate in refractory hairy cell leukemia. 61
1708945 1991

Variations for Refractory Hairy Cell Leukemia

Expression for Refractory Hairy Cell Leukemia

Search GEO for disease gene expression data for Refractory Hairy Cell Leukemia.

Pathways for Refractory Hairy Cell Leukemia

GO Terms for Refractory Hairy Cell Leukemia

Cellular components related to Refractory Hairy Cell Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 9.76 MSLN IL2RA HLA-DRB1 FURIN EEF2 CD22
2 membrane raft GO:0045121 9.43 FURIN EEF2 CD19
3 external side of plasma membrane GO:0009897 9.26 IL2RA HLA-DRB1 CD22 CD19
4 cell surface GO:0009986 9.02 MSLN IL2RA HLA-DRB1 FURIN CD22

Biological processes related to Refractory Hairy Cell Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of T cell proliferation GO:0042130 8.96 IL2RA HLA-DRB1
2 inflammatory response to antigenic stimulus GO:0002437 8.62 IL2RA HLA-DRB1

Molecular functions related to Refractory Hairy Cell Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 CD4 receptor binding GO:0042609 8.62 HLA-DRB1 CD22

Sources for Refractory Hairy Cell Leukemia

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
69 Tocris
71 UMLS via Orphanet
Loading form....